The purpose of this study was to determine the effects of subchronic exposure to the antihistamine pyrilamine maleate and to establish dosage levels to use in a 2-year chronic study. A 14-day repeated-dose study in male and female B6C3F1 mice at dietary levels of pyrilamine (as the free base) of 0,196,392,783,1563, or 3122 ppm revealed no influence on body weight gain and resulted in no deaths, nor abnormal clinical or gross necropsy observations. Parotid gland cell necrosis was more apparent in high-dosage groups than in controls of either gender. Male and female B6C3F1 mice also were administered pyrilamine for 90 days at dietary concentrations of 0,375,750,1500,3000, or 6000 ppm. Weight gain was markedly suppressed in the 6000 ppm group, but less so at 1500 and 3000 ppm. Parotid gland cell necrosis was apparent in males receiving 750 ppm pyrilamine and above and in females at 1500 ppm and above. Cytomegaly was noted in the parotid glands of both sexes at midlevel dosages but not in control, low-dosage, or high-dosage animals. It was concluded that 1500 ppm pyrilamine would not belife-threatening to B6C3F, mice in a chronic study.
INTRODUCTION
YRILAhlINE BELONGS TO THE EXHYLENEDIAhllNE C h S S Of antihistamines. specific USeS O f pyrilamine take P advantage of its anticholinergic, antitussive, antiemetic, and sedative effects in addition to its antihistaminic actions. It has been used effectively in the management of seasonal (hay fever) and nonseasonal allergic rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild urticaria and angiocdema due to allergic skin reactions. dermographism, and treatment of motion sickness. It has been used also as a cough suppressant to control cough due to cold or allergies. Pyrilamine maleate is the most commonly used form of the antihistamine present in drug formulations.
The acute toxicity of pyrilamine was reviewed by Haley (1948) . Pyrilamine maleate has an oral LD,, of 338 mgkg in mice. The LD,, was 102 rndkg in mice when given intraperitonealIy (Lewis andTatken, 1980) . Signs of acute toxicity of pyrilamine include Struab tail phenomenon, squeaking, restlessness, generalized tremor, increased activity, convulsions, and death by asphyxia (Haley, 1948) .
Chronic exposure of rats to pyrilamine has given negative or suggestive evidence that this drug may be carcinogenic. Lijinsky (1984) exposed Fischer344 rats to 2000 ppm in either the feed or drinking water and found some evidence for hepatocellular carcinogenicity in animals exposed to the antihistamine in their feed. More recently Habs et al. (1986) found no evidence of carcinogenicity upon chronic exposure of Sprague-Dswley rats to drinking water concentrations of 550 or I100 ppm pyrilarninc.
'Office of Scientific Coordination, 'Biometry Staff, and ZPathology Associates, Incorporated, National Center for Toxicological Research, Jefferson, AR. primarynthepatocytecultures (Probst andNeal, 1980; McQueenandWilliams. 1981; Budroeetal., 1984) and its mutagenicity in the mouse lymphoma assay in the presence but not in the absence of Aroclor-induced rat-liver S9 (Tumeret al., 1987) ..
Pyrilamine maleate was selected for carcinogenicity studies because of its structural similarity to another antihistamine, methapyrilene, which has been clearly demonstrated to be a liver carcinogen in Fischer 344 rats (Lijinsky et al., 1980) . Its presence in numerous over-the-counter drug formulations, its increased use since the carcinogenicity of methapyrilene was first demonstrated, its gcnotoxicity in mammalian systems, and suggestive evidence for hepatocarcinogenicity in rats all have contributed to its selection for testing.
This study was designed to determine the subchronic toxicity of pyrilamine in B6C3F, mice and provide data for selecting dosage levels to be used in a 2-year carcinogenesis study.
hlATERIALS AND hlETIIODS
Pyrilaminc maleate, 2-[[2-(Dimethylamino)ethyl)@-methoxy-benzyl)amino]pyridine maleate, (CAS No. 59-33-6) was obtained from Hexagon Laboratories, Inc. (lot no. 71-1 11-3hl) . Chemical purity of the product was established as essentially I00%, with no extraneous peaks observed using high-performance liquid chromatography (HPLC) and g a~ chromatographylflame ionization detection (GCIFID) analyses.
Pyrilamine maleate, dissolved in 95% ethanol (USP), was mixed with autoclaved Purina 5010hl meal feed in a 2 cubic foot blender. Control feed was mixed with an equivalent volume of 95% ethanol. After being mixed, the ethanol was evaporated under vacuum, and random samples of mixed doses were chemically analyzed for pyrilamine. Dietary concentrations are expressed as parts per million (ppm) of the free amine rather than as the maleate. Pyrilamine, stored in dosed feed at ambient temperature (70-75" F) was found to be stable for up to 16 weeks.
B6C3F, mice were produced under strict banier conditions at the National Center for Toxicological Research (NCTR) from stock originally obtained from the National Institutes of Health Repository.
Dosing of mice was begun when they were about 5 weeks old. Average males weighed 20-21 g and females 17-18 g when allocated to the study. Mice were fed diets containing 0, 196, 392, 783, 1563, or 3122 ppm pyrilamine for 14 days (6 mice per gender per dosage group) or 0,375,750, 1500,3000, or 6ooo ppm for 90 days (12 mice per gender per dosage group). The feeder used in the study was designed to minimize spillage to allow estimation of food use by weight of the feeder before and after it had been in the cage for I week.
hlice were housed, 3 (14 days) or 4 (90 days) per cage on hardwood chip bedding in polycarbonate cages capped with polyester filter bonnets. Room temperature and relative humidity (RH) were controlled within limits of 70-74" F and 40-608, respectively, with about I7 changes of room air per hour. The room was kept on a 12 hr lighfldark cycle. Males and females were housed in separate columns on the same cage racks. Feed and water were available on demand. Feeders, water bottles, cages, and bedding were changed weekly. Checks for dead or moribund animals were made once or twice a day. Animal weights and feed use were determined weekly. hlice were killed by CO, anesthesia on the 15th day or on the 89th to 92nd day after a 24 hr recovery period on control diet followed by overnight fasting. Necropsies were performed on all animals. A complete histopathologic examination of over 40 organs was performed on all high-dosage and untreated control mice of the 90-day study. The only target organ, determined from the high dosage group, was the parotid salivary gland, which also was examined in the lower-dosage groups. In addition, brain, liver, right kidney, thymus, heart, lungs, and right testis were weighed from mice surviving till the end of the study. In the 90-day study blood was collected for analysis of serum enzymes, alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT), in 375, 1500, 6000 ppm, and control groups.
hleans and standard deviations were routinely calculated for pertinent data and, where applicable, statistical comparisons were made using a Statistical Analysis System (79.5 version) package compatible with the NCTR lBhl4341 main frame computer. hlean organ to body weight and organ to brain weight ratios of each dosage group were compared to control group mean ratios by B test procedure developed by Williams (1971 Williams ( , 1972 to determine the lowest effective dosage at which an effect is evident. This procedure involves adjustment of mean terminal body weights for differences between first dosing body weights by analysis of covariance, and dosage group adjusted means were compared to control group adjusted mean for each gender by a two-tailed 1-test. Female 21.4 f 1.5 21.3 f 1.1 20.6 f 1.0 20.3 f 1.6 20.6 f 1.6 21.1 +-1.1 17.9 f 0.9 17.8 f 0.9 16.9 t 0.5 17.9 t 1.1 17.7 f 1.1
Analysis of clinical chemistry data was complicated by the fact that only animals from one or two treatment groups were killed on a given day. Thus, it was not possible to evaluate interactions between dosage and day of sampling. A one-way analysis of variance was performed in which each dose and day combination was a level of a factor called day-dose. A significant day-dose effect does not tell whether it is a measure of differences between days or doses. However, since males in the control and highest dose group were killed on the same day, a comparison of these two groups should be valid for assessing the effect of dose.
RESULTS

14-D~ry s t d y
Initial and final body weights are summarized in Table 1 . There were no significant differences in terminal weights noted foreither male or female B6C3F1 mice. However, average weight gain in animals in the high-dosage group tended to be lower than in controls, espccially in females. Weekly measurements of food consumption seemed to indicate higher consumption at the two highest dosages than in controls, especially by females (average daily consumption in glfemale: controls, 3.4 g; 1563 ppm, 4.0 g; 3122 ppm, 4.2 g). However, feed wastage was not measured and cannot be ruled out as an explanation of the data.
All animals survived the duration of the study, and no abnormal clinical observations were noted during the course of the study.
During necropsy, no significant gross lesions were observed. Furthermore, histologic examination of specified tissues and organs revealed no dosage-related lesions in animals of either gender. Although parotid salivary glands had not been specified for histologic examination in the 14-day study, after cytomegaly and cell necrosis were detected in these glands in the 90-day study, the parotid glands from control and highest dosage groups of the 14-day study were evaluated. The results of this evaluation are presented in Table 2 . Although cell necrosis was found among controls it was more frequent and notably more severe among treated mice and was considered to be related to treatment.
90-Day stdJ1
During the first week of the 90-day study animals of both genders fed 3000 or 6000 ppm pyrilamine either lost weight or gained less weight than controls (Figure I) . Furthermore, average terminal body weights of all pyrilamine-treated mice were less than their controls, and this was especially apparent among animals fed the two Body weights of B6C3F, mice fed pyrilamine for 90 days. Control, -% 375 ppm, -C, 750 ppm, -a, (Table 3 ). Due to an unusually low average starting weight of female mice fed 6000 ppm pyrilamine, statistical comparisons of terminal weights were made only after adjusting for differences in start weights by covariance analysis. Adjusted terminal weights were significantly lower than controls in the three highest dosage groups of males and only at the 3000 ppm level among female groups (Table 3) . Apparent food consumption during the experiment was higher in both genders fed 3000 or 6OOO ppm pyrilamine than in all other treatment groups (Table 3 ). These differences appeared during the first week ofthe experiment and, although they became somewhat less apparent, persisted throughout the study. Since feed wastage w3s not measured during the study, palatability problems could have caused feed scattering in the high-dosage groups. Nevertheless, average maximum daily dosages of pyrilamine were estimated using the apparent food consumption data (Table 3) .
Clinical observations associated with chemical treatment of females were emaciation, noted only during the first 8 days of the study (2/12,3000 ppm; 9/12,6000 pprn), and alopeciaover much of the body that appeared after 10 weeksofexposure(2Il2.6000ppm). Inrnalesfed6000ppmpyrilamineforabout 1 I weeks2il2 werehunchedand the same number had alopecia over much of the body. Only three mice died during the study. These were all females in the two highest dosage groups (3000 ppm, 1; 6000 ppm, 2). No gross abnormalities were apparent at necropsy. No significant differences in the concentration of serum alanine aminotransferase were found at the termination of the study among mice of either gender fed 0, 375, 1500, or 6000 ppm pyrilamine. Although aspartate aminotransferase levels were significantly (p < 0.05) reduced in several pyrilamine-treated groups ( Table 4 ) when compared to controls, these differences did not contribute to adosage-related trend, and were noted between groups killed on different days than the controls. Thus, they probably were not treatment-related.
Organ weight group means, summarized in Table 5 , generally were lower than controls in the 3000 and 6000 ppm groups. When comparisons were made among dosage group mean organ weights, adjusted for differences in starting body weights, significant differences between treated and control group means tended to be erratic, without showing dosage trends. The exceptions were with female adjusted liver and brain weights. Adjusted liver weights were higher (p < 0.005) in both 3000 and 6000 ppm groups. Adjusted brain weights were higher (p < 0.05) in 6OOO ppm females than in controls.
When organ weight to body weight ratios of treated groups were compared with control ratios, treatment-related statistically significant increases were noted in brain, liver, kidney, testis, and thymus ratios of males and in brain, liver, and kidney ratios of females ( Table 5 ). In each of these instances, except thymus, orgadbody weight ratios were significantly greater (p < .01) in mice fed either 3000 or 6000 ppm pyrilamine than in controls. A significant increase (p < .05) in the thymusbody weight ratio was noted in males fed only the highest dosage level. The kidney/body weight ratio of males was significantly greater than controls in all dosage groups ( Table 5) .
Comparisons of group mean orgadbrain weight ratios of treated groups with controls revealed a significant increase in the thymusbrain ratio only in the 6000 ppm males ( Table 5 ). Significant decreases in hedbrain, kidney/brain, and liver/brain ratios were noted in both sexes. These were present only at the highest dosage, with the exception that the headbrain ratio of males was also decreased in the 3000 ppm group ( Table 5) .
The only compound-related histopathologic finding in the initial evaluation of control and highest dosage groups was an increase in the frequency and severity of individual cell necrosis in the parotid salivary gland of males and females fed 6000 pprn pyrilamine. Subsequent evaluation of parotid glands of all dosage groups revealed an increased incidence of necrosis in males at 750 ppm and above and in females at 1500 ppm and above (Table 6 ) . Cytomegaly, consisting of diffuse enlargement of parotid gland parenchymal cells, was also observed in animals of both genders at dietary pyrilamine levels of 750 pprn and above (Table 6) . However, the incidence of cytomegaly rose to a peak at 750 ppm in males, 1500 ppm in females, and declined to zero at 6000 ppm ( Table 6 ).
DISCUSSION
In the 14-day study, there was some evidence of a biological effect of pyrilamine. Cell necrosis was found in the parotid salivary gland, in both male and female mice fed 3122 ppm pyrilamine, but there was no evidence of toxicity. Even body weight gain was not significantly suppressed at 3122 ppm. Thus, the highest dosage selected for the 90-day study was 6000 ppm.
In the 90-day study, effects of pyrilamine on body weight were the only evidence of toxicity. During the initial phase of the study pyrilamine levels of 3000 and 6000 ppm inhibited weight gain or caused weight loss in both genders during the first week of administration. Furthermore, weight gain of both males and females fed 3000 or 6000 pprn pyrilamine was depressed throughout the study. In males there was a progressive decrease in final body weight with increasing pyrilamine dosage, starting at the lowest dosage. Although there were several significant increases in organ/body weight ratios noted at the two highest dosage levels, these were probably related to effects on body weight rather than to direct toxic effects upon the specific organs. This interpretation is supported by the disappearance of dosage-related positive effects when organhain weight ratios were compared and by a failure to detect specific histologic alterations related to increased orgadbody weight ratios.
Interpretation of the histologic changes noted in the parotid salivary gland is difficult. Cytomegaly and individual cell necrosis have been observed with other antihistamines (Jackson et al., 1990a.b; Jackson and Blackwell, 1991a,b) , and it has been suggested that these observations simply may reflect physiological responses to the antihistamines (Jackson and Blackwell, 1991 b) . Antihistamines are known for their anticholinergic activity, which inhibits salivation and might explain cytomegaly. However, the rise in incidence of cytomegaly at low dosages and decline at high dosages is not readily explained. Although the antihistamine tripelennamine induced parotid gland cytomegaly in both rats and mice (Jackson and Blackwell, 1991a,b) , in those studies no biphasic 'Animals received dietary pryilamine at the indicated concentrations for 90 days. The incidence reported is the number of animals exhibiting parotid gland necrosis or cytomegalylnumbcr of animals examined.
bSignificant positive trend (p < 0.002). 'Significant positive trend (p < 0.0001).
effect was noted. Although cell necrosis may represent a toxic effect of pyrilamine on the parotid gland, this appears to be a response characteristic of antihistamines (Jackson and Blackwell, 1991a,b) rather than specific to pyrilamine.
In summary, pyrilamine maleate administered to B6C3Ft mice in the feed at dosages as high as 6000 ppm for 14 or 90 days produced little or no toxicity except for decreased weight gain at 3000 and 6OOO ppm. Histologic alterations of the parotid salivary gland noted at 750 ppm and above were not thought to have serious toxicologic implications. It was concluded that a dietary level of 1500 ppm would not be life-shortening to either male or female B6C3F, mice in a 2 year chronic study.
